TriFabs-trivalent IgG-shaped bispecific antibody derivatives: Design, generation, characterization and application for targeted payload delivery

International Journal of Molecular Sciences

Volumn 16, Issue 11, 2015, Pages 27497-27507

  Mayer, Klaus ^a   Baumann, Anna Lena ^a   Grote, Michael ^a   Seeber, Stefan ^a   Kettenberger, Hubert ^a   Breuer, Sebastian ^a   Killian, Tobias ^a   Schäfer, Wolfgang ^a   Brinkmann, Ulrich ^a  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

CD33; Disulfide stabilization; GPC3; Imaging; Knob into hole; LeY; Payload delivery; Saporin

Indexed keywords

ANTIBODY CONJUGATE; BISPECIFIC ANTIBODY; DISULFIDE; DRUG CARRIER; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; PROTEIN BINDING;

ANTIBODY AFFINITY; BINDING SITE; CHEMISTRY; DRUG DELIVERY SYSTEM; GENETIC ENGINEERING; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; TEMPERATURE;

ANTIBODIES, BISPECIFIC; ANTIBODY AFFINITY; BINDING SITES; DISULFIDES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EPITOPES; GENETIC ENGINEERING; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; TEMPERATURE;

EID: 84947460200     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161126037     Document Type: Article

References (30)

1. Kontermann, R.E.; Brinkmann, U. Bispecific antibodies. Drug Discov. Today 2015, 20, 838-847
2. Weidle, U.H.; Kontermann, R.E.; Brinkmann, U. Tumor-antigen-binding bispecific antibodies for cancer treatment. Semin. Oncol. 2014, 41, 653-660
3. Wu, C.; Ying, H.; Grinnell, C.; Bryant, S.; Miller, R.; Clabbers, A.; Bose, S.; McCarthy, D.; Zhu, R.R.; Santora, L.; et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat. Biotechnol. 2007, 25, 1290-1297
4. Metz, S.; Panke, C.; Haas, A.K.; Schanzer, J.; Lau, W.; Croasdale, R.; Hoffmann, E.; Schneider, B.; Auer, J.; Gassner, C.; et al. Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng. Des. Sel. 2012, 25, 571-580
5. Baeuerle, P.A.; Reinhardt, C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009, 69, 4941-4944
6. Kontermann, R.E.; Wing, M.G.; Winter, G. Complement recruitment using bispecific diabodies. Nat. Biotechnol. 1997, 15, 629-631
7. Merchant, A.M.; Zhu, Z.; Yuan, J.Q.; Goddard, A.; Adams, C.W.; Presta, L.G.; Carter, P. An efficient route to human bispecific IgG. Nat. Biotechnol. 1998, 16, 677-681
8. Johnson, G.; Wu, T.T. Kabat database and its applications: 30 years after the first variability plot. Nucleic Acids Res. 2000, 28, 214-218
9. Klein, C.; Sustmann, C.; Thomas, M.; Stubenrauch, K.; Croasdale, R.; Schanzer, J.; Brinkmann, U.; Kettenberger, H.; Regula, J.T.; Schaefer, W. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 2012, 4, 653-663
10. Reiter, Y.; Brinkmann, U.; Jung, S.H.; Pastan, I.; Lee, B. Disulfide stabilization of antibody Fv: Computer predictions and experimental evaluation. Protein Eng. 1995, 8, 1323-1331
11. Metz, S.; Haas, A.K.; Daub, K.; Croasdale, R.; Stracke, J.; Lau, W.; Georges, G.; Josel, H.P.; Dziadek, S.; Hopfner, K.P.; et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc. Natl. Acad. Sci. USA 2011, 108, 8194-8199
12. Ishiguro, T.; Sugimoto, M.; Kinoshita, Y.; Miyazaki, Y.; Nakano, K.; Tsunoda, H.; Sugo, I.; Ohizumi, I.; Aburatani, H.; Hamakubo, T.; et al. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res. 2008, 68, 9832-9838
13. Dengl, S.; Hoffmann, E.; Grote, M.; Wagner, C.; Mundigl, O.; Georges, G.; Thorey, I.; Stubenrauch, K.G.; Bujotzek, A.; Josel, H.P.; et al. Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies. FASEB J. 2015, 29, 1763-1779
14. Hoffmann, E.; Konkar, A.; Dziadek, S.; Josel, H.P.; Conde-Knape, K.; Kropp, H.; Kling, L.; Stubenrauch, K.; Thorey, I.; Dengl, S.; et al. PK modulation of haptenylated peptides via non-covalent antibody complexation. J. Control. Release 2013, 171, 48-56
15. Schneider, B.; Grote, M.; John, M.; Haas, A.; Bramlage, B.; Ickenstein, L.M.; Jahn-Hofmann, K.; Bauss, F.; Cheng, W.; Croasdale, R.; et al. Targeted siRNA delivery and mRNA knockdown mediated by bispecific digoxigenin-binding antibodies. Mol. Ther. Nucleic Acids 2012, 1, e46
16. Feige, M.J.; Hendershot, L.M.; Buchner, J. How antibodies fold. Trends Biochem. Sci. 2010, 35, 189-198
17. Bertz, M.; Buchner, J.; Rief, M. Mechanical stability of the antibody domain CH3 homodimer in different oxidation states. J. Am. Chem. Soc. 2013, 135, 15085-15091
18. Jarasch, A.; Koll, H.; Regula, J.T.; Bader, M.; Papadimitriou, A.; Kettenberger, H. Developability assessment during the selection of novel therapeutic antibodies. J. Pharm. Sci. 2015, 104, 1885-1898
19. Ewert, S.; Huber, T.; Honegger, A.; Plückthun, A. Biophysical properties of human antibody variable domains. J. Mol. Biol. 2003, 325, 531-553
20. He, F.; Hogan, S.; Latypov, R.F.; Narhi, L.O.; Razinkov, V.I. High throughput thermostability screening of monoclonal antibody formulations. J. Pharm. Sci. 2010, 99, 1707-1720
21. Weidle, U.H.; Tiefenthaler, G.; Schiller, C.; Weiss, E.H.; Georges, G.; Brinkmann, U. Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer. Cancer Genom. Proteom. 2014, 11, 25-38.
22. Idusogie, E.E.; Presta, L.G.; Gazzano-Santoro, H.; Totpal, K.; Wong, P.Y.; Ultsch, M.; Meng, Y.G.; Mulkerrin, M.G. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 2000, 164, 4178-4184
23. DeLano, W.L.; Ultsch, M.H.; de vos, A.M.; Wells, J.A. Convergent solutions to binding at a protein-protein interface. Science 2000, 287, 1279-1283
24. Graille, M.; Stura, E.A.; Corper, A.L.; Sutton, B.J.; Taussig, M.J.; Charbonnier, J.B.; Silverman, G.J. Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc. Natl. Acad. Sci. USA 2000, 97, 5399-5404
25. Roopenian, D.C.; Akilesh, S. FcRn: The neonatal Fc receptor comes of age. Nat. Rev. Immunol. 2007, 7, 715-725
26. Yip, V.; Palma, E.; Tesar, D.B.; Mundo, E.E.; Bumbaca, D.; Torres, E.K.; Reyes, N.A.; Shen, B.Q.; Fielder, P.J.; Prabhu, S.; et al. Quantitative cumulative biodistribution of antibodies in mice: Effect of modulating binding affinity to the neonatal Fc receptor. MAbs 2014, 6, 689-696
27. Van de Watering, F.C.; Rijpkema, M.; Robillard, M.; Oyen, W.J.; Boerman, O.C. Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry. Front. Med. 2014
28. Nagorsen, D.; Baeuerle, P.A. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp. Cell Res. 2011, 317, 1255-1260
29. Bonin-Debs, A.L.; Boche, I.; Gille, H.; Brinkmann, U. Development of secreted proteins as biotherapeutic agents. Expert Opin. Biol. Ther. 2004, 4, 551-558
30. Rossi, E.A.; Goldenberg, D.M.; Chang, C.H. Complex and defined biostructures with the dock-and-lock method. Trends Pharmacol. Sci. 2012, 33, 474-481